共 50 条
- [1] The Ratio of CD8 to Treg Tumor Infiltrating Lymphocytes Is Associated with Neoadjuvant Cisplatin Based Chemotherapy Response in Patients with Muscle Invasive Urothelial Carcinomas of the BladderMODERN PATHOLOGY, 2016, 29 : 216A - 216ABaras, AlexanderDrake, CharlesLiu, Jen-JaneGandhi, NilayKates, MaxHogue, MohamedMeeker, AlanHahn, Noah M.Schoenberg, MarkTaube, JanisBivalacqua, Trinity J.Netto, George J.
- [2] The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladderONCOIMMUNOLOGY, 2016, 5 (05):Baras, Alexander S.Drake, CharlesLiu, Jen-JaneGandhi, NilayKates, MaxHoque, Mohamed O.Meeker, AlanHahn, NoahTaube, Janis M.Schoenberg, Mark P.Netto, GeorgeBivalacqua, Trinity J.
- [3] CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinomaPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (10) : 3967 - 3972Sharma, PadmaneeShen, YuWen, SijinYamada, SachikoJungbluth, Achim A.Gnjatic, SachaBajorin, Dean F.Reuter, Victor E.Herr, HarryOld, Lloyd J.Sato, Eiichi
- [4] Tumor infiltrating lymphocytes (TIL) assessment in muscle invasive bladder cancer (MIBC) patients treated with cisplatin-based neoadjuvant chemotherapy (NAC) and surgeryJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)Chanza, Nieves MartinezHamid, AnisSalgado, RobertoGevaert, ThomasMaetens, MarionRorive, SandrineAftimos, Philippe GeorgesSideris, SpyridonGil, ThierryAwada, AhmadRoumeguere, Thierry Andre
- [5] Baseline CD4/CD8 tumor infiltrating lymphocytes (TIL) ratio predicts pathologic response to neoadjuvant chemotherapy (NC) in breast cancerCANCER RESEARCH, 2012, 72Garcia-Martinez, E.Luengo, Gil G.Chaves, Benito A.Garcia, Garcia T.Vicente, Conesa A. M.Zafra, Poves M.Garcia, Garre E.Vicente, Garcia V.Ayala, de la Pena F.
- [6] PREDICTORS OF RESPONSE FOLLOWING NEOADJUVANT CISPLATIN BASED CHEMOTHERAPY FOR MUSCLE INVASIVE UROTHELIAL BLADDER CANCER USING MOLECULAR PROFILEJOURNAL OF UROLOGY, 2022, 207 (05): : E974 - E974Elkarta, AhmedElhefnawy, AhmedAbol-Enein, HassanShokeir, Ahmed
- [7] Multidisciplinary management and use of neoadjuvant cisplatin combination chemotherapy in patients with muscle-invasive urothelial bladder cancerJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Hoffman-Censits, Jean H.Lin, JianqingLallas, Costas D.Showalter, Timothy NormanDen, Robert BenjaminDoubet, EllenBrown, JillianSingh, JaspreetDicker, AdamGomella, Leonard G.Kelly, William KevinTrabulsi, Edouard John
- [8] Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder CancerADVANCES IN UROLOGY, 2013, 2013Lee, Franklin C.Harris, WilliamCheng, Heather H.Shenoi, JaideepZhao, SongWang, JunfengChampion, ThomasIzard, JasonGore, John L.Porter, MichaelYu, Evan Y.Wright, Jonathan L.
- [9] Quantitative assessment of CD3, CD8, and CD20 in tumor-infiltrating lymphocytes and predictive value for response to neoadjuvant chemotherapy in breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Brown, Jason R.Bai, YalaiBossuyt, VeerleNixon, ChristianLannin, Donald R.Rimm, David L.
- [10] Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experienceCUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (3-4): : E287 - E293El-Gehani, FarajNorth, ScottGhosh, SunitaVenner, Peter